AMRX
HealthcareAmneal Pharmaceuticals, Inc. · Drug Manufacturers - Specialty & Generic · $4B
What is Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals is a mid-cap healthcare company that develops, manufactures, and distributes both generic and branded pharmaceutical products across multiple therapeutic areas. Headquartered in Bridgewater, New Jersey, it serves retail, institutional, and government customers.
Amneal operates through three segments. Its Generics segment produces complex oral solids, injectables, ophthalmics, topicals, and inhalation products. The Specialty segment focuses on branded drugs targeting central nervous system disorders, endocrinology, and parasitic infections — including treatments for Parkinson's disease and hypothyroidism. The AvKARE segment supplies pharmaceuticals, medical products, and surgical supplies primarily to government agencies including the Department of Defense and the Department of Veterans Affairs.
Amneal Pharmaceuticals was incorporated in 2018 and is headquartered in Bridgewater, New Jersey.
- Generic pharmaceuticals across multiple dosage forms and therapeutic categories
- Rytary, a branded treatment for Parkinson's disease
- Emverm, a chewable tablet for parasitic infections
- Unithroid for hypothyroidism management
- Government pharmaceutical and medical supply distribution via AvKARE
Is AMRX a Good Stock to Buy?
UQS Score rates AMRX as Below Average overall.
Among the five pillars, Valuation stands out as the relative bright spot — AMRX's Valuation pillar is rated Attractive, suggesting the market may be pricing in significant headwinds. The Growth pillar registers as Neutral, meaning the company is not in outright decline but has not demonstrated the kind of consistent expansion that would elevate its overall profile.
The Quality, Moat, and Risk pillars all carry Weak ratings, reflecting concerns around business durability, competitive positioning, and financial resilience that weigh heavily on the composite score.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AMRX pay dividends?
No — Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
Amneal Pharmaceuticals does not currently pay a dividend. For a company carrying Weak Quality and Risk pillar ratings, capital is more likely directed toward debt management and operational needs rather than shareholder distributions. Investors seeking income from the healthcare sector may need to look elsewhere, while those focused on potential value recovery may weigh the Attractive Valuation rating instead.
When does AMRX report earnings?
Amneal Pharmaceuticals reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Neutral Growth pillar suggests results have been neither strongly positive nor sharply deteriorating in recent periods. Given the Weak Quality and Risk ratings, investors tend to watch cash flow generation and debt levels closely each quarter.
For the most recent quarter's results and guidance updates, visit Amneal Pharmaceuticals' investor relations page directly.
AMRX Price History
+130.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Amneal Pharmaceuticals, Inc.?
Based on Amneal Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AMRX Long-term Outlook
The fundamental outlook for AMRX is mixed. A Neutral Growth pillar indicates the business has some forward momentum — particularly through its Specialty and AvKARE segments — but Weak Quality and Risk pillars suggest the path forward carries meaningful uncertainty. The Attractive Valuation rating implies the current price may reflect a discount relative to peers, though that discount could reflect genuine structural challenges rather than a simple market mispricing.
Growth drivers
- Expansion of the branded Specialty portfolio targeting underserved therapeutic areas
- Government supply contracts through the AvKARE segment providing recurring revenue
- Pipeline of complex generic products in higher-barrier dosage forms
Key risks
- Elevated debt load and Weak Risk pillar raise concerns about financial flexibility
- Generic drug pricing pressure and competition can compress margins across the Generics segment
- Weak Moat rating suggests limited pricing power and brand differentiation relative to peers
AMRX vs Peers
Amneal competes across different corners of the pharmaceutical landscape, with peers ranging from specialty-focused operators to diversified branded and generic drug companies.
Indivior is narrowly focused on addiction treatment therapies, giving it a more concentrated specialty profile compared to Amneal's broader generics and government distribution mix.
Lantheus specializes in diagnostic imaging agents, operating in a distinct niche within healthcare that differs significantly from Amneal's generics-heavy business model.
Bausch Health is a larger diversified pharmaceutical and medical products company, sharing some overlap in branded drugs but operating at a different scale and with a distinct portfolio focus.
Frequently Asked Questions
What does Amneal Pharmaceuticals do?
Amneal Pharmaceuticals develops, manufactures, and distributes generic and branded pharmaceutical products. It operates through three segments: Generics, which covers a wide range of dosage forms; Specialty, which focuses on branded drugs for conditions like Parkinson's disease and hypothyroidism; and AvKARE, which supplies pharmaceuticals and medical products to government agencies.
Does AMRX pay dividends?
Amneal Pharmaceuticals does not currently pay a dividend. Given its Weak Quality and Risk pillar ratings, the company appears to prioritize managing its financial obligations over returning capital to shareholders. Income-focused investors may find better options elsewhere in the healthcare sector.
When does AMRX report earnings?
Amneal Pharmaceuticals follows a standard quarterly earnings cadence for US-listed companies. For confirmed dates and the most recent results, check the company's official investor relations page, as specific calendar dates are subject to change.
Is AMRX a good stock to buy?
UQS Score rates AMRX as Below Average, driven by Weak ratings across Quality, Moat, and Risk pillars. The Valuation pillar is rated Attractive, which may interest contrarian investors, but the overall profile suggests meaningful risks. The complete pillar breakdown is available to UQS Pro members.
Is AMRX overvalued?
Based on the UQS Valuation pillar, AMRX is rated Attractive — meaning the stock does not appear expensive relative to its fundamentals and sector peers. However, an attractive valuation can reflect genuine business challenges rather than a hidden opportunity, particularly given the Weak Quality and Risk ratings.
How does AMRX compare to its competitors?
Amneal operates across generics, specialty branded drugs, and government distribution — a broader mix than peers like Indivior, which focuses on addiction treatment, or Lantheus, which specializes in diagnostic imaging. Bausch Health is a closer structural peer in terms of diversification. UQS Pro members can view side-by-side pillar comparisons.
What is AMRX's market cap bracket?
Amneal Pharmaceuticals is classified as a mid-cap company. This places it in a segment of the market that can offer more growth potential than large-caps but typically carries more volatility and less financial resilience than larger pharmaceutical peers.
Who founded Amneal Pharmaceuticals?
Amneal Pharmaceuticals was founded by brothers Chirag and Chintu Patel. The company was incorporated in its current public form in 2018 following a business combination. Further founding history is widely available through public sources and the company's own disclosures.
Is AMRX a long-term quality investment?
As a long-term quality indicator, AMRX's UQS profile raises caution. Weak ratings across Quality, Moat, and Risk pillars suggest the business lacks the durable competitive advantages and financial strength typically associated with long-term compounders. The Attractive Valuation may appeal to value-oriented investors willing to accept higher uncertainty.
What is the main competitive advantage of Amneal Pharmaceuticals?
Amneal's Moat pillar is rated Weak, indicating limited durable competitive advantages relative to peers. Its broadest differentiator is operational scale across generics, specialty branded products, and government supply channels — but this diversification has not translated into a strong moat by UQS criteria.
What sector does AMRX belong to?
Amneal Pharmaceuticals operates in the Healthcare sector, specifically within pharmaceutical manufacturing and distribution. It spans both the generic drug market and the branded specialty drug space, while also serving government healthcare procurement through its AvKARE segment.
Unlock Full AMRX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare AMRX side-by-side with sector peers
- ✓Screen for higher-quality healthcare stocks using UQS filters
- ✓Get the complete analyst-style quality breakdown in one place
Pro Analysis
AMRX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 46.6 | 42.0 | 22.0 | 55.0 | 42.7 | 87.8 | -0.2 |
| May 22, 2026 | 46.8 | 42.5 | 22.0 | 55.0 | 42.7 | 88.8 | -0.3 |
| May 21, 2026 | 47.1 | 42.5 | 22.0 | 55.0 | 42.7 | 90.5 | -0.1 |
| May 20, 2026 | 47.2 | 42.5 | 22.0 | 55.0 | 42.7 | 91.4 | +0.1 |
| May 17, 2026 | 47.1 | 42.5 | 22.0 | 55.0 | 42.7 | 90.6 | -0.1 |
| May 16, 2026 | 47.2 | 42.5 | 22.0 | 55.0 | 42.7 | 91.3 | +0.1 |
| May 15, 2026 | 47.1 | 42.1 | 22.0 | 55.0 | 42.7 | 91.2 | +0.1 |
| May 14, 2026 | 47.0 | 42.1 | 22.0 | 55.0 | 42.7 | 90.7 | 0.0 |
| May 13, 2026 | 47.0 | 41.7 | 22.0 | 55.0 | 42.7 | 91.2 | +0.1 |
| May 12, 2026 | 46.9 | 41.7 | 22.0 | 55.0 | 42.7 | 90.7 | +0.3 |
AMRX — Pillar Breakdown
Quality
— 42.0/100 (25%)Amneal Pharmaceuticals, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 55.0/100 (20%)Amneal Pharmaceuticals, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 42.7/100 (15%)Amneal Pharmaceuticals, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 89.0/100 (15%)Amneal Pharmaceuticals, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 22/100 (25%)Amneal Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AMRX.
Score Composition
Financial Data
More Stock Analysis
How is the AMRX UQS Score Calculated?
The UQS (Unified Quality Score) for Amneal Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Amneal Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Amneal Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.